Pamplona (PRWEB) September 27, 2013
3P Biopharmaceuticals will participate in the European research project FLUTCORE, financed by the European Union 7th Framework Programme (FP7). The consortium is comprised of several prestigious companies and research centers specialized in influenza virus research.
The European consortium will be led by iQur Ltd., which is a biotech company based in London, whose research into the tandem core™ vaccine platform forms the basis of the science behind the project. Their vaccine platform has been shown to generate powerful immune responses to several pathogens, and this consortium will optimize their influenza candidate vaccine for use in the clinical setting.
Currently, flu vaccines are seasonal and need to be renewed on a yearly basis to be effective. Therefore, the development of a universal vaccine that does not require annual modification, and that is as effective for new virus strains as for existing ones, is considered a priority for the European Union. Furthermore, existing influenza vaccines are manufactured in fertilized chicken eggs, so the incorporation of recombinant technology, used in the iQur process, constitutes an important competitive advantage.
The other members of the consortium include Leeds University and University College of London Hospital from UK, CRP Santé from Luxemburg, the Latvijas Medicinal centre from Lituania and Institut Catala de la Salut from Spain.
Within the context of this project, 3P will be responsible for producing high-quality vaccine material suitable for both for preclinical assays in animals and for Phase I clinical trial.
3P Biopharmaceuticals is a leading European GMP certified CMO (Contract Manufacturing Organization) based in Pamplona, specialized in the manufacturing of novel biologic drugs as vaccines or monoclonal antibodies as well as Biosimilars (highly similar biologic drugs to the ones in the market).
Custom manufacturing of Biologics from mammalian, yeast, and bacterial systems are developed from proof of concept to commercial stages being able to adapt to regulatory requirements for every phase. An integral and complete bioproduction service with a wide range of related services is offered by 3P.
3P is involved together with its customers in very early phase of development, preclinical assays, and clinical assays until commercial phases.
“iQur is excited to be leading such an illustrious consortium and delighted that 3P Pharmaceuticals has decided to participate. The inclusion of a major manufacturer of vaccines is vital since the production of clinical trial material to the highest safety standards is an absolute requirement for the success of the project”, states Mike Whelan, R&D Director of iQur. Additionally, Dámaso Molero, General Manager of 3P Biopharmaceuticals, comments that this agreement will allow 3P “to position themselves in the highly technically demanding European market together with strategic companies of recognized prestige“.
Visit http://www.3pbio.com/ for more information and details.